Showing results (531-540 of 587) with videos related to

Sort By:
Pageof 59
The Lancet. Oncology|June 12, 2021
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 studyJustin F Gainor, Giuseppe Curigliano, Dong-Wan Kim, et al.
Lung Cancer (Amsterdam, Netherlands)|October 24, 2025
Real-world outcomes of second-line carboplatin plus pemetrexed after first-line osimertinib in EGFR-mutant advanced NSCLC: An international multicentre cohort studyIgor Gomez-Randulfe, Federico Monaca, Ornella Cantale, et al.
European Journal of Cancer (Oxford, England : 1990)|November 5, 2025
EORTC 1417 - REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancerJessica Menis, Laurent Greiller, Pierre Demontrond, et al.
Cancer Discovery|September 13, 2024
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound MutationsJessica J Lin, Joshua C Horan, Anupong Tangpeerachaikul, et al.
European Urology Oncology|March 4, 2024
Development of Novel Models of Aggressive Variants of Castration-resistant Prostate CancerLudovic Bigot, Jonathan Sabio, Loic Poiraudeau, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 3, 2019
Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO expertsPaul M Putora, Markus Glatzer, José Belderbos, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 25, 2019
Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO expertsPaul Martin Putora, Markus Glatzer, Dirk De Ruysscher, et al.
The New England Journal of Medicine|September 9, 2017
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung CancerScott J Antonia, Augusto Villegas, Davey Daniel, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 23, 2026
First-line integration of Local Ablative Therapy (LAT) with EGFR Tyrosine Kinase Inhibitors (TKIs) in advanced EGFR+ NSCLC: A Systematic Review and Meta-AnalysisLeonardo Brunetti, Giacomo Colella, Giuseppina Rita Di Fazio, et al.
Pageof 59